rheumatoid arthritis - JAK-1 Inhibitor Effective for RA, but Safety Signal Troubles

The oral JAK-1 inhibitor upadacitinib is showing a strong response in active rheumatoid arthritis that has responded inadequately to biologics; however, concern lingers about...